2024 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
| ESMO OPEN |
2024 | Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials
| CANCER RESEARCH AND TREATMENT |
2024 | Neoadjuvant chemotherapy followed by definitive local treatment in locally advanced sinonasal squamous cell carcinoma
| FRONTIERS IN ONCOLOGY |
2024 | Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea
| Lung Cancer : targets and therapy |
2024 | Safety and anti-tumor activity of BAY 2927088 in patients with <i>HER2</i>-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study. | JOURNAL OF CLINICAL ONCOLOGY |
2024 | Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2024 | A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)
| ONCOIMMUNOLOGY |
2024 | Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09
| BMC CANCER |
2024 | A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma | CLINICAL CANCER RESEARCH |
2024 | Feasibility of UTE-MRI-based radiomics model for prediction of histopathologic subtype of lung adenocarcinoma: in comparison with CT-based radiomics model | EUROPEAN RADIOLOGY |
2024 | Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722
| JOURNAL OF CLINICAL ONCOLOGY |
2024 | Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial | JOURNAL OF CLINICAL ONCOLOGY |
2024 | A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): In-Depth Analysis of Nintendanib Arm from the KCSG HN 15-16 TRIUMPH Trial
| CANCER RESEARCH AND TREATMENT |
2024 | Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma
| CANCER RESEARCH AND TREATMENT |
2023 | Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer
| LUNG CANCER |
2023 | Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC
| JOURNAL OF THORACIC ONCOLOGY |
2023 | Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
| JTO Clinical and Research Reports |
2023 | A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
| CANCER RESEARCH COMMUNICATIONS |
2023 | Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
| CANCER MEDICINE |
2023 | First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial
| CANCER MEDICINE |
2023 | Dynamic change of immune phenotype assessed by artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) during neoadjuvant durvalumab with or without tremelimumab (D+/-T) in head and neck squamous cell carcinoma (HNSCC)
| JOURNAL OF CLINICAL ONCOLOGY |
2023 | Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
| TRANSLATIONAL LUNG CANCER RESEARCH |
2023 | Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study | LUNG CANCER |
2023 | Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
| CANCER RESEARCH AND TREATMENT |
2023 | Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
| JTO Clinical and Research Reports |
2023 | Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
| DRUGS-REAL WORLD OUTCOMES |
2023 | The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer
| KOREAN JOURNAL OF INTERNAL MEDICINE |
2023 | A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation
| CANCER |
2023 | Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity
| YONSEI MEDICAL JOURNAL |
2023 | Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01)
| CANCERS |
2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
2022 | Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2022 | Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
| CLINICAL LUNG CANCER |
2022 | YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment
| FRONTIERS IN CHEMISTRY |
2022 | Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer
| RADIATION ONCOLOGY |
2022 | Role of postoperative radiotherapy in resected adenoid cystic carcinoma of the head and neck
| RADIATION ONCOLOGY |
2022 | Neoadjuvant Immunotherapy Following Definitive Surgical Treatment for Locoregionally Advanced Head and Neck Cancer: Perioperative Complication and Surgical Outcomes
| Korean Journal of Otorhinolaryngology-Head and Neck Surgery |
2022 | Regulatory T cells in the tumour microenvironment of head and neck cancer: Emerging target in the era of immunotherapy
| Clinical and Translational Discovery |
2022 | Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation
| THERANOSTICS |
2022 | Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience | CANCER IMMUNOLOGY IMMUNOTHERAPY |
2022 | Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
| LUNG CANCER |
2022 | Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2022 | A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
| JOURNAL OF THORACIC ONCOLOGY |
2022 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
| CLINICAL CANCER RESEARCH |
2022 | Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice
| CURRENT ONCOLOGY |
2022 | Disproportional enrichment of FoxP3(+)CD4(+) regulatory T cells shapes a suppressive tumourmicroenvironment in head and neck squamous cell carcinoma
| CLINICAL AND TRANSLATIONAL MEDICINE |
2022 | Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy | RADIOTHERAPY AND ONCOLOGY |
2022 | The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
| FRONTIERS IN ONCOLOGY |
2022 | Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | NEW ENGLAND JOURNAL OF MEDICINE |
2022 | SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
| CLINICAL & TRANSLATIONAL IMMUNOLOGY |